[Section 1.51] of the License Agreement is hereby amended by adding “to the extent” immediately following “solely” in the first sentence.

[Exhibit 1.20].2 is hereby amended and replaced in its entirety with the following:

[Section 1.1] of the Agreement is hereby amended to add the following new defined terms:

[Section 1.01] of the Loan and Servicing Agreement is hereby amended by adding the following definition in proper alphabetical sequence:

[Section 1.1] of the Existing Credit Agreement is hereby amended by adding the following defined terms in appropriate alphabetical order:

[Schedule 1.01(b)] to the Credit Agreement is hereby amended and restated to read in its entirety as set forth on Annex I hereto.

[Section 1.01] (Defined Terms) of the Credit Agreement is hereby amended by replacing the defined terms “Eurodollar Rate”, “Maturity Date”, and “Replacement Rate” in their entirety with the following corresponding terms:

[Section 1.1(76)] of the Transaction Agreement is hereby deleted in its entirety and replaced with the following:

[Schedule 1.9] sets forth a complete and accurate list of all [[AstraZeneca:Organization]] Patents in existence as of the Effective Date, indicating the owner or co-owners thereof (including Affiliates of [[AstraZeneca:Organization]]), if such [[AstraZeneca:Organization]] Patent is not solely owned by [[AstraZeneca:Organization]];

[Section 1.02] (Other Interpretive Provisions) of the Credit Agreement is amended by adding a new clause (d) thereto as follows: